Optimizing Treatment in Bipolar Disorder: Review & New Directions-View Presentation Slides

View Presentation Slides

Pdf Summary

Mark A. Frye’s APA presentation reviews current treatment optimization and emerging directions in bipolar disorder. Bipolar disorder affects 1.5–3% of adults (about 40 million people worldwide), is often misdiagnosed for years, and is associated with major disability, high economic cost, and a 10–20 year reduction in life expectancy driven partly by medical comorbidity. The talk highlights diagnostic and clinical features that help distinguish bipolar from unipolar depression (e.g., hypersomnia, hyperphagia, early onset, recurrent episodes, family history, and antidepressant-induced activation).<br /><br />Treatment goals are framed as true mood stabilization: efficacy across acute manic/mixed and depressive episodes, avoidance of mood switching, and relapse prevention. FDA-approved options span atypical antipsychotics and classic mood stabilizers. Lithium remains the “gold standard” for acute mania and long-term prevention, with evidence for suicide risk reduction, but response varies by subtype (poorer outcomes with rapid cycling, mixed features, and substance use). Valproate is emphasized for acute mania (with a dose/serum-level response relationship) and possible benefits in depression and prophylaxis, but with notable metabolic and teratogenic risks. Typical antipsychotics may be rapidly effective for mania but carry EPS risks and may worsen depressive course. Olanzapine/samidorphan is presented as an efficacy-preserving approach with less weight gain than olanzapine.<br /><br />Comorbidity strongly shapes outcomes and prescribing. Psychiatric comorbidity is common (anxiety, substance use disorders, borderline personality disorder) and is linked to more rapid cycling, higher suicidality, more polypharmacy, greater benzodiazepine and antidepressant exposure, and lower lithium use. Cardiometabolic burden (obesity, insulin resistance, hypertension, and increased cardiovascular events) is positioned as a key treatment target; evidence is reviewed for metformin benefits in insulin-resistant, treatment-resistant bipolar depression and for GLP-1 agonists improving weight and metabolic outcomes in stable bipolar patients.<br /><br />Controversies include antidepressants in bipolar depression (limited efficacy signal in bipolar I; clearer potential utility in bipolar II in selected studies). New research directions include ketogenic diet interventions, adjunctive wake-promoting/stimulant strategies (e.g., modafinil evidence; mixed amphetamine salts trial negative), lower-dose lithium, integration of bipolar care into primary care, and a “learning health network” model (BD2 Integrated Network) using longitudinal digital/EHR/biologic data to rapidly improve care.

Keywords

bipolar disorder

mood stabilization

lithium

valproate

atypical antipsychotics

bipolar vs unipolar depression diagnosis

psychiatric comorbidity

cardiometabolic risk

antidepressants in bipolar depression

learning health network (BD2 Integrated Network)